Project Grant R01DA058665
Award Date
8/15/24
Completion Date
5/31/28
Dollars Obligated
$1.8M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
The National Institute on Drug Abuse (NIDA) awarded a $643,978 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to See Yourself Health LLC, a woman-owned small business in Beverly, MA. The grant titled "The CHIRON Project: Using Virtual Reality to Prevent Substance Use Disorder in Healthcare Workers Facing Burnout" aims to develop an immersive virtual reality platform that enables healthcare professionals to access confidential peer support, evidence-based...
The National Institute on Drug Abuse (NIDA) awarded a $959,964 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Charles River Analytics, Inc. to design and demonstrate the feasibility of a prototype system called Stimulant Use Recovery via Immersive Virtual Environments (SURVIVE). The goal of SURVIVE is to provide controlled environmental triggers and cognitive behavioral therapy (CBT) embedded into virtual environments to treat stimulant use disorder (STUD),...
The National Institute on Drug Abuse (NIDA) awarded Duke University a Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and validate digital envirotyping methods for characterizing the everyday environments of people who smoke. The $763,766 award, which runs from July 2025 to March 2030, aims to (1) advance digital envirotyping and enviromarker development to identify environmental triggers of smoking relapse, and (2) increase understanding of...
This Project Grant award of $2,594,198.00 from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), supports research to elucidate the neural circuitry linked to smoking and the genetic influences on it. The study will use the UK Biobank neuroimaging dataset to examine habenula functional connectivity with the salience network and ventral tegmental area, and the influence of genomic variations on this connectivity. It will compare...
The National Institute on Drug Abuse (NIDA) awarded a $1,076,018 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to Dynamicare Health Inc. in Wareham, MA. The award will fund a Phase II randomized clinical trial to evaluate the efficacy of DCH-003, a digital therapeutic that delivers contingency management for the treatment of stimulant use disorder. The trial will compare standard clinic care plus DCH-003 to standard care plus a sham digital app, with the...
This Project Grant award of $320,000 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop a smoking and vaping cessation treatment based on the drug candidate cytisine. The goal is to explore the feasibility of delivering cytisine through electronic vape administration (EVA) to help stabilize dopamine release and reduce nicotine self-administration in a mouse model of nicotine addiction. Key activities include...
This federal Project Grant award of $800,617.00, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the development and validation of neuromarkers - measurable, brain-based indicators of pathophysiology, risk, and resilience related to substance use disorders (SUDs). The project, titled "NEUROMARKERS FOR CRAVING AND DRUG USE", aims to build upon previous research that created a cross-validated neuromarker...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), will support a $2,075,613 research project conducted by the Regents of the University of Michigan. The project aims to validate a human sign-/goal-tracking paradigm and identify neurobehavioral signatures of sign- and goal-tracking behaviors in emerging adults, which are key to understanding individual differences in addiction liability. The...
This Project Grant award of $2,415,940.00, awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to develop digital biomarkers and phenotypes for tracking craving patterns in individuals with opioid use disorder (OUD) during medication-based treatment (MOUD). The award will fund a prospective, observational trial of 300 participants initiating MOUD with buprenorphine, methadone or naltrexone. Continuous wearable...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $395,566 to Flik Therapeutics, Inc. to support the development of a novel FDA-regulated pharmacotherapy and multimodal nicotine cessation program. The goal is to create a more effective smoking cessation therapy compared to the current standard of care, which has low success rates. This Phase I proposal will fund the initial development of the...